Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)

NCT07292519 on ClinicalTrials.gov · last registry update 2025-12-18

A small phase 2 — 46 participants, against a typical 110. Due to report 15 May 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Heavy Drinking Days. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for alcohol use disorder — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: South West Sydney Local Health District
Sponsor type: Other
Enrollment: 46
Started: 2026-01-15
Primary completion: 2027-05-15 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Heavy Drinking Days

Conditions studied

Alcohol Use Disorder (AUD) · Overweight or Obese · Comorbidities and Coexisting Conditions

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.